FDA Grants Fast Track Designation For Prevail's Parkinson's Treatment

Prevail Therapeutics PRVL shares are trading higher after the company received FDA fast track designation for PR001 for the treatment of Parkinson's disease patients with a GBA1 mutation.

“We are pleased that the FDA has granted Fast Track Designation for PR001, which underscores the unmet need of patients with Parkinson’s disease with a GBA1 mutation, a chronic and progressive neurodegenerative disorder that comprises 7% to 10% of the total Parkinson’s disease population worldwide,” said CEO Asa Abeliovich.

“With no treatments available that modify the progressive course or the underlying disease process of Parkinson’s disease, a potential disease-modifying therapy like PR001 could significantly transform the lives of patients with this disease.”

Prevail Therapeutics shares traded higher by 6.5% to $11.20 at time of publication. The stock has a 52-week high of $16.90 and a 52-week low of $9.83.

Related Links:

Prevail Therapeutics Opens Below IPO Price

Sol-Gel Technologies Shares Positive Results For Skin Breakout Cream